AHCC09
Find out about the STRATUM trial (AHCC09), a Phase II study testing SIRT-Y90 combined with atezolizumab and bevacizumab in patients with locally advanced liver cancer.
Trial summary of AHCC 09
AHCC09 | A multi-national, double-blind, placebo-controlled, parallel randomized arms, phase II trial to compare the safety and efficacy of SIRT-Y90 followed by atezolizumab plus bevacizumab versus SIRT-Y90 followed by placebo in patients with locally advanced hepatocellular carcinoma (HCC) (STRATUM) (NCT05377034) |
|---|---|
Status | Recruiting |
Contributing Principal Investigators and Centres | Singapore Pierce Chow (National Cancer Centre), Toh Han Chong (National Cancer Centre), Chee Cheng Ean (National University Hospital) Overseas sites include: South Korea Kim Yoon Jun (Seoul National University Hospital), Kim Seung Up (Severance Hospital, Yonsei University Health System), Lee Joon Hyeok (Samsung Medical Centre) Taiwan Hsu Chiun (National Taiwan University Cancer Center), Liang Po-Chin (National Taiwan University Hospital), Lee Teng-Yu (Taichung Veterans General Hospital), Huang Yi-Hsiang (Taipei Veterans General Hospital), Chen Chao-Long (Kaohsiung Chang Gung Memorial Hospital) China mainland Feng Xiaobin (Beijing Tsinghua Changgung Hospital), Zeng Yong (West China Hospital, Sichuan University), Liu Rong (People's Liberation Army General Hospital), Sun Xiaorong (Shandong Cancer Hospital), Liu Jibing (Shandong Cancer Hospital) |
Protocol Chair | Pierce Chow |